Immuron's Reset: Record Sales, a Stronger Balance Sheet, and a New Strategy

MELBOURNE, Australia – August 28, 2026 – Australian biopharmaceutical firm Immuron Limited has announced a significant financial and strategic turnaround, reporting record sales and key clinical advancements that position its unique antibody platform to address a widening network of infectious diseases, from common traveler's ailments to critical military health threats.

Following a "Strategic Reset" initiated in February 2026, the company exceeded its own projections, signaling a new phase of growth and a clear strategy to commercialize its most promising assets through high-value partnerships. The results highlight a successful pivot from a company burning cash on R&D to one with a strengthened balance sheet and a de-risked path to market for its late-stage drug candidates.

Financial Fortitude Fuels Future Growth

Immuron's preliminary results for the fiscal year ending June 30, 2026, paint a picture of a company regaining its financial footing. The firm posted record global sales revenue of A$7.7 million, a 6% increase over the prior year, driven largely by its flagship product, Travelan®, an over-the-counter supplement for preventing traveler's diarrhea.

This top-line growth was supported by strong performance in key markets. Australian sales surged by 10% to A$5.8 million, fueled by effective digital marketing campaigns and a rebound in regional travel. In the United States, a critical growth market, sales climbed 13% in USD terms to reach A$1.8 million. While the Canadian market was down for the full year, a dramatic 100% sales increase in the second half of the fiscal year suggests momentum is building.

More importantly, the company demonstrated improved operational efficiency and financial discipline. Net loss after tax was significantly reduced by 26.4% to A$3.8 million, a A$1.4 million improvement from the A$5.2 million loss in FY25. This was achieved in part by a strategic reduction in direct R&D expenditure, which fell from A$3.6 million in FY25 to A$1.9 million in FY26, as the company shifts its focus toward partnering its clinical assets rather than funding late-stage trials alone.

This disciplined approach has dramatically strengthened Immuron's balance sheet. The company's cash reserves swelled from A$2.8 million to A$9.0 million, providing a crucial financial runway to execute its strategic plans for FY27, which include further investment in North American growth and advancing partnership discussions.

A Strategic Pivot to Partnerships

The cornerstone of Immuron's strategic reset is a decisive shift toward partnering its two key clinical assets, IMM-124E and IMM-529. This move is designed to de-risk development, leverage the resources and expertise of larger pharmaceutical players, and accelerate the path to commercialization, a common and often effective playbook for smaller biotech firms with valuable assets.

IMM-124E, the core component of Travelan®, is being developed as a prescription therapeutic for traveler's diarrhea and is now eligible for an End-of-Phase-2 meeting with the U.S. Food and Drug Administration (FDA). Market analyst firm Lumanity has projected potential peak U.S. sales for this indication at US$102 million, highlighting a significant commercial opportunity beyond its current supplement status.

Even more promising is IMM-529, a therapeutic candidate for Clostridioides difficile infection (CDI), a dangerous and often recurring bacterial infection that poses a major threat in hospital settings. With an Investigational New Drug (IND) application already approved by the FDA in November 2025, IMM-529 is ready to enter Phase 2 clinical trials. The potential here is substantial, with Lumanity estimating peak U.S. sales could reach US$400 million. Recognizing the asset's value, Immuron engaged Pullan Consulting in July 2026 to specifically support the partnering process for IMM-529. This strategic focus aims to unlock the drug's value without Immuron shouldering the immense cost and risk of late-stage clinical development and commercial launch.

The Biological Network: From Traveler's Gut to National Defense

Underpinning these commercial and clinical developments is Immuron's proprietary platform technology, which creates orally delivered polyclonal antibodies from hyper-immune bovine colostrum. This biological "infrastructure" provides a targeted defense system for the gut, neutralizing specific pathogens at their point of entry. By vaccinating cows against specific bacteria or viruses, the company can produce colostrum rich in antibodies that can withstand the human digestive system and bind to invaders, preventing them from colonizing the gut.

This platform's versatility is becoming increasingly apparent. While Travelan® targets the E. coli strains most commonly responsible for traveler's diarrhea, IMM-529 takes on the far more complex challenge of C. difficile. It employs a unique three-pronged attack, with antibodies targeting not only the primary toxin (Toxin B) but also the bacterial spores and vegetative cells. This approach has shown promise in preclinical models for preventing initial infection, treating active disease, and, critically, preventing recurrence—the hallmark of CDI.

The platform's potential has also attracted the attention of the U.S. military. In December 2025, Immuron signed a research agreement, funded by a U.S. Department of Defense sub-award, with the Naval Medical Research Command and Walter Reed Army Institute of Research. The goal is to develop novel hyper-immune bovine colostrum products targeting Campylobacter and Shigella. These bacteria are among the leading causes of infectious diarrhea, a condition that poses a significant threat to the health and operational readiness of deployed military personnel. This collaboration not only provides external validation and non-dilutive funding for Immuron's research but also opens a pathway to address a critical need within the global defense network.

The Road Ahead: North American Expansion and Clinical Milestones

With a fortified balance sheet and a clear strategic roadmap, Immuron, led by CEO Steven Lydeamore, is poised for a transformative year. The company's outlook for FY27 is focused on execution across its commercial and clinical fronts. Key near-term milestones include driving continued growth for Travelan®, particularly in North America, and expanding its portfolio, likely through new distribution agreements like its existing one for ProIBS®.

However, all eyes will be on the progress of its partnering activities. The company anticipates reporting significant progress on securing a partner for IMM-529 in the third quarter of the fiscal year. A successful deal would serve as a major validation of its new strategy, provide a significant source of non-dilutive funding, and move a potential half-billion-dollar drug one step closer to patients in need. As the company works to expand its geographic footprint and improve profitability, its ability to leverage its unique antibody platform through strategic collaborations will be the ultimate test of its successful reset.